Another possible mechanism of resistance to STI571

被引：6
|
作者：
Knight, ZA [1 ]
机构：
[1] Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA
来源：
BLOOD | 2000年 / 96卷 / 12期
关键词：
D O I：
10.1182/blood.V96.12.4003.h8004000d_4003_4005
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4003 / 4004
页数：2
相关论文
共 50 条
  • [21] Pityriasis rosea associated with imatinib (STI571,Gleevec)
    Konstantopoulos, K
    Papadogianni, A
    Dimopoulou, M
    Kourelis, C
    Meletis, J
    DERMATOLOGY, 2002, 205 (02) : 172 - 173
  • [22] Effects of STI571 on radioimmunotherapy of colorectal cancer.
    Baranowska-Kortylewicz, J
    Abe, M
    Kurizaki, T
    Pietras, K
    Ostman, A
    Kortylewicz, ZP
    Enke, CA
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6189S - 6189S
  • [23] Severe periorbital edema secondary to STI571 (Gleevec)
    Esmaeli, B
    Prieto, VG
    Butler, CE
    Kim, SK
    Ahmadi, MA
    Kantarjian, HM
    Talpaz, M
    CANCER, 2002, 95 (04) : 881 - 887
  • [24] Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
    Weisberg, E
    Griffin, JD
    BLOOD, 2000, 95 (11) : 3498 - 3505
  • [25] STI571 (imatinib mesylate): the tale of a targeted therapy
    Thambi, P
    Sausville, EA
    ANTI-CANCER DRUGS, 2002, 13 (02) : 111 - 114
  • [26] Does Theobromine Increase the Apoptotic Effect of STI571?
    Kasap, Yesim Korkmaz
    Ozdemir, Zeynep
    Asparuk, Cagan
    Ak, Oguzhan
    Aysun, Dide
    Akgor, Doga
    Elmastas, Fulya
    Akkus, Dogukan
    Yurtcu, Erkan
    GAZI MEDICAL JOURNAL, 2016, 27 (04): : 193 - 197
  • [27] Cancer treatment in the STI571 era: What will change?
    Sawyers, CL
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) : 13S - 16S
  • [28] Impact of STI571 on the pharmacokinetics of etoposide and / or ifosfamide in mice
    Decaudin, Didier
    Rezai, Keyvan
    Grandjean, Isabelle
    Weill, Sophie
    Arnaud, Philippe
    Ekue, Richard
    Garcia, Mickael
    Poupon, Marie-France
    Lokiec, Francois
    CANCER RESEARCH, 2006, 66 (08)
  • [29] The Role of the Tyrosine Kinase Inhibitor STI571 in the Treatment of Cancer
    O'Dwyer, Michael E.
    Druker, Brian J.
    CURRENT CANCER DRUG TARGETS, 2001, 1 (01) : 49 - 57
  • [30] Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571
    Tabrizi, R
    Mahon, FX
    Makhoul, PC
    Lagarde, V
    Lacombe, F
    Berthaud, P
    Melo, JV
    Reiffers, J
    Belloc, F
    LEUKEMIA, 2002, 16 (06) : 1154 - 1159
12345